 |
|
|
|
 |
| JULY
9,
2009 | ISSUE NUMBER 106 VOL 8 |
Regulatory
FDA Boosts Warnings on Propoxyphene Pain Meds
Pain medications containing propoxyphene could lead to overdose and death, according to new labeling mandated by FDA. However, public requests to take these drugs (including Darvon and Darvocet) off the market have been denied.
Approvals
Sanofi Gets Green Light on Blockbuster Heart Treatment
Sanofi-Aventis is banking that its highly anticipated atrial fibrillation/flutter treatment Multaq will be a huge success. The path to approval has been ridden with a failed trial and a very long review process, but for Sanofi, the wait has been worth it.
Strategy
Caraco Pharma Eliminates 350 Jobs
Generics firm Caraco released more than half its employees, after FDA seized more than 30 of its products and shut down manufacturing. The good news? When it resumes manufacturing, Caraco is approved to market a generic form of Casodex, AstraZeneca’s prostate drug.
New Media
Is the Online Revolution Working for Pharma?
Agency Insider Mark Chattaway infiltrates the world of online social media. His consensus: Advertising on social networks is iffy at best?
Global
Last NICE Word on Alzheimer’s Meds
UK Health Institute leaves guidance unchanged in case against Eisai and Pfizer; more research on NICE methodology needed.
Featured Story
Emerging Leaders 2009: The Faces of Innovation
Pharm Exec’s second annual Emerging Leadership Awards cast the spotlight on 27 young rising stars most notable for their dedication and contribution to the pharma industry. Here's a closer look at why.
|
 |
|  Horizon Therapeutics appointed Jeffrey W. Sherman, MD, as its executive vice president and chief medical officer //Watson Pharmaceuticals appointed Christopher W. Bodine to its board of directors //Wake Pharm US appointed Jeffrey A. Niezgoda, MD, as director of the company’s medical advisory board //Cadence Pharmaceuticals made Scott Byrd senior vice president and chief commercial officer //
Rib-X Pharmaceuticals appointed Russell Greig to its board of directors//Robert Zwick joined International Medical News Group as classified sales manager//MicroMass Communications appointed Richard Patterson to vice president, group account director//Aton Pharma’s CEO Michael G. Wells received the Ernst & Young Entrepreneur Of The Year 2009 award in the emerging companies category//Juice Pharma Worldwide wins Perfect Global Partner Award at the annual Worldwide Partners World Meeting
|
|
|
|
July
30–31 CBI’s
4th Clinical Supply Chain Management Conference,
Princeton, NJ
August
11–22 3rd Annual Forum on Tracking State Laws and Aggregate Spend,
Arlington, VA
September
14–15 4th Annual Forum on Educational Grants for the Bio/Pharmaceutical Industry,
Philadelphia, PA
September
21–24 5th
Annual Process Excellence Week for the Service & Transactional
World, Chicago, IL
October
5–7 BioNetwork
2009: The 7th Annual Pharmaceutical-Biotech Partnering
Conference, Laguna Niguel, California |
|
|
|
 |
|
 |
|
 |
| Should the Department of Justice end pharma’s tactic of paying off other firms to postpone generic competition? |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.To
ensure delivery to your Inbox, please add %%email.list%% to your
address book. If you need help doing this, click
here.
Advanstar
Communications provides certain customer contact data (such as customers'
names, addresses, phone numbers and e-mail addresses) to third parties
who wish to promote relevant products, services and other opportunities
which may be of interest to you. If you do not want Advanstar Communications
to make your contact information available to third parties for
marketing purposes, simply call (toll free) 1-866-529-2922 at any
time, or fax us at 1-218-740-6417. Outside the U.S., please phone
1-218-740-6395. Contact us by mail at Advanstar Communications Inc.,
131 West First St., Duluth, MN 55802-2065, USA. |
|
